Jiangxi Heying's Prunella Vulgaris Oral Liquid Wins NMPA Registration, Ending Guiyang Xintian's Long Monopoly

Jiangxi Heying Pharmaceutical's Prunella vulgaris oral liquid received an NMPA registration certificate (Guoyao Zhunzi Z20263002) on September 2, 2026, and was approved for marketing. The article calls it the third same-name same-formula traditional Chinese medicine nationally and in practice the first approved without a technical linkage, and says its approval ends Guiyang Xintian Pharmaceutical's long-standing monopoly. The drug is an oral liquid made from a single herbal ingredient, classified as a prescription drug under medical insurance category B.